Occlusion Location | DSA (No.) (%) | 3D-TOF MRA (No.) (%) | GRE T2 (No.) (%) | TR-CE MRA (No.) (%) |
---|---|---|---|---|
No occlusion (no susceptibility vessel sign for GRE T2) | 0 (0%) | 0 (0%) | 6 (17.6%) | 0 (0%) |
ExCICA | 3 (8.8%) | 5 (14.7%) | 0 (0%) | 3 (8.8%) |
IICA | 0 (0%) | 5 (14.7%) | 0 (0%) | 0 (0%) |
SCICA | 8 (23.5%) | 3 (8.8%) | 3 (8.8%) | 9 (26.5%) |
M1 | 17 (50.0%) | 20 (58.8%) | 22 (64.7%) | 19 (55.9%) |
M2 | 6 (17.6%) | 1 (2.9%) | 2 (5.9%) | 3 (8.8%) |
κ | 0.43 | 0.31 | 0.81 | |
95% CI | 0.26−0.60 | 0.15−0.48 | 0.60−1 | |
(% of agreement) | 61.8% | 55.9% | 88.2% |
↵a Intracranial occlusion location with 3D-TOF, GRE T2, and TR-CE MRA, compared with DSA as the standard reference, showing the occlusion level detected as well as κ and percentage of agreement with DSA for each MRI sequence.